No abstract available.
Axis, Cervical Vertebra*

OBJECTIVE: This study is to evaluate the efficacy of Intracytoplasmic Sperm Injection(ICSI) for previous fertilization failure with conventional in vitro fertilization(IVF), compared with ICSI for male factor. METHOD: The author analyzed the 3 years of clinical experience with ICSI retrospectively, between the conventional IVF failure group (IVF failure) and male factor group (male factor). Surgically retrieved epididymal or testicular spermatozoa for ICSI were excluded. The IVF failure group was 13 cycles of 6 patients and male factor group was 30 cycles of 15 patients. RESULTS: The fertilization rates of the IVF failure group and male factor group were 63% and 66% respectively (p=0.635). The clinical pregnancy rates of the both group were 23.1% and 26.7% (p=0.804), and that of live birth rates were 15.4% and 13.3% (p=0.858). There were no significant difference between the two groups. CONCLUSION: The author concluded that ICSI can overcome previous fertilization failure, with the same fertilization and clinical pregnancy rates seen in patients with male factor.
Fertilization in Vitro* ; Fertilization* ; Humans ; Live Birth ; Male ; Pregnancy Rate ; Retrospective Studies ; Sperm Injections, Intracytoplasmic* ; Spermatozoa

OBJECTIVE: This study is to investigate the clinical efficacy of low-dose FSH regimen, comparing with clomiphene citrate and human menopausal gonadotropin (CC/hMG) regimen. METHODS: Retrospective study of the ovulatory factor infertility 39 patients who had been treated by intrauterine insemination (IUI). The 31 cycles of 21 patients were stimulated by CC/hMG regimen, the 22 cycles of 18 patients were stimulated by low-dose FSH regimen. We compared the rate of clinical pregnancy, multiple pregnancy and ovarian hyperstimulation syndrome (OHSS) of both group. RESULTS: The rate of clinical pregnancy of the CC/hMG group was 25.7% per cycle, and that of the low-dose FSH group was 54.5% per cycle. The low-dose FSH group showed a higher rate of clinical pregnancy per cycle than CC/hMG group (p=0.028). However, no differences was found statistically in the rate of multiple pregnancy and OHSS between CC/hMG group (22.2%, 5.7%) and low-dose FSH group (33.3%, 13.6%). CONCLUSION: This study showed that the low-dose FSH regimen is superior to CC/hMG regimen in getting clinical pregnancy, but dose not reduce the ovulation induction complications.
Pregnancy ; Female ; Humans

PURPOSE:Bone mineral mass increases with age, weight and pubertal development. Several factors influence the process of bone mineralization, and evaluation of bone mineral density(BMD) in children gives important clue to the different mechanisms of bone mass accumulation. To investigate the abnormality in bone mineralization, the normal range of bone mineral content in healthy children should be understood. The pattern, time and velocity in the decrease of bone mineral contents depend on disease entities. Because the ratio of trabecular and cortical bones and turn-over rates differ in each bone, it is needed to make normal data for trabecular and cortical bones respectively in children. METHODS:In 75 children(40 boys) with normal growth and development, BMD was measured with XR26 Bone densitometry using DEXA. The BMD of trabecular bone was obtained at lumbar spine at 2-4 level, and that of cortical bone was measured at femur neck. RESULTS:The BMD of trabecular bone increased with age without sexual difference. But the BMD of cortical bone was higher in male significantly at 8-9 and 10-11 yr of age. In both male and female, the BMD of trabecular and cortical bones correlated positively with age, bone age, height, weight, and body surface area. CONCLUSION: With this data, the changes in BMD affected by several diseases could be assessed.
Body Surface Area ; Bone Density* ; Calcification, Physiologic ; Child* ; Densitometry ; Female ; Femur Neck ; Growth and Development* ; Humans ; Male ; Reference Values ; Spine

We experienced a boy manifesting sexual precocity with unilateral testicular tumor, who was finally diagnosed as CAH with 21-hydroxylase deficiency. Initial laboratory findings were compatible with peripheral precocious puberty. Ultrasonogram for testes showed heterogenous high echoic mass in the right testicle. Radical orchiectomy was performed and its pathology revealed benign Leydig cell tumor without Reinke crystal. But, testosterone was not decreased after 1 month of surgery. Second laboratory exam revealed increased DHEA-S and 17-hydroxyprogesterone. Finally, this case was recognized as CAH(simple virilizing type) with unilateral testicular adrenal rest tumor. In conclusion, CAH should always be considered during etiologic study for the male sexulal precocity even with unilateral testicular tumor.
17-alpha-Hydroxyprogesterone ; Adrenal Hyperplasia, Congenital ; Adrenal Rest Tumor ; Humans ; Leydig Cell Tumor* ; Male ; Orchiectomy ; Pathology ; Puberty, Precocious ; Steroid 21-Hydroxylase ; Testis ; Testosterone ; Ultrasonography

No abstract available.
Congenital Hypothyroidism*

No abstract available.
Child* ; Ear* ; Humans

We experienced two cases of congenital adrenal hyperplasia(CAH), complicated by true precocious puberty with early maturation of the hypothalamic-pituitary-gonadal axis in a boy and a girl. The boy was diagnosed as CAH at 8 years of age, when he showed pseudoprecocity with adrenal rest tumor. The girl was diagnosed at neonate, when she showed ambiguous genitalia and salt-losing symptom. They developed precocious puberty during steroid treatment. Clinically they showed precocity, advanced bone age, and decreased predicted adult height, even though they showed partial gonadotrophin response to luteinizing hormone releasing hormone (LHRH) stimulation test. They were treated with LHRH analogue(leuprolide depot) resulting no further progression of precocity.
Adrenal Hyperplasia, Congenital* ; Adrenal Rest Tumor ; Adult ; Axis, Cervical Vertebra ; Disorders of Sex Development ; Female ; Gonadotropin-Releasing Hormone ; Humans ; Infant, Newborn ; Male ; Puberty, Precocious*

Behavioral symptoms are well-recognized concomitants of the progression of dementia. These symptoms include agitation, aggression, anxiety, depression, disinhibition, delusions, hallucination, and sleep disturbance. Because these symptoms are a major source of impaired quality of life for patients and their caregivers, appropriate pharmacological management of them may reduce the burden of caregivers and postpone institutionalization. Furthermore, behavioral symptoms may be more amenable to pharmacological intervention than cognitive symptoms. For that reason, detailed evaluation and appropriate treatment are the mainstay in the management of dementia patients. In this article, we reviewed symptomatology and psychopharmacology for behavioral symptoms of dementia.
Aggression ; Alzheimer Disease ; Anxiety ; Behavioral Symptoms* ; Caregivers ; Delusions ; Dementia* ; Depression ; Dihydroergotamine ; Hallucinations ; Humans ; Institutionalization ; Neurobehavioral Manifestations ; Psychopharmacology ; Quality of Life

No abstract available.
Depression* ; Immune System* ; Psychoneuroimmunology* ; Schizophrenia*